C
HUTCHMED (China) Limited HCM
$14.26 $0.000.00% NASDAQ
Recommendation
Prev Close
$14.26
Volume
10,873
Avg Vol (90D)
45,885
Market Cap
$2.51B
Dividend & Yield
--
52-Week Range
$11.51 - $19.50
P/E (TTM)
26.91
EPS (TTM)
$0.53
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
HUTCHMED (China) (HCM, $14.42) Stochastic Oscillator left the oversold zone on November 28, 2025
11/29/2025 - Tickeron - Stocks
HUTCHMED to Present New Clinical Data at 2025 ESMO and ASH Meetings
11/27/2025 - TipRanks Financial Blog
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
11/27/2025 - Globe Newswire
HUTCHMED (China) (HCM, $14.22) RSI Indicator left the oversold zone on November 24, 2025
11/25/2025 - Tickeron - Stocks
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Recommendation of "Hold" from Brokerages
11/23/2025 - MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Recommendation of "Hold" from Brokerages
11/22/2025 - Ticker Report
HUTCHMED (China) (HCM, $14.18) RSI Indicator left the oversold zone on November 20, 2025
11/21/2025 - Tickeron - Stocks
HUTCHMED (China) (HCM, $14.66) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 18, 2025
11/19/2025 - Tickeron - Stocks
HUTCHMED (China) (HCM, $14.66) Stochastic Oscillator left the oversold zone on November 18, 2025
11/19/2025 - Tickeron - Stocks
HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at Wall Street Zen
11/16/2025 - MarketBeat
HUTCHMED (NASDAQ:HCM) Lowered to Hold Rating by Wall Street Zen
11/8/2025 - MarketBeat
CICC Remains a Buy on HUTCHMED (China) (HCM)
11/8/2025 - TipRanks Financial Blog
HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM
11/7/2025 - Market News Video
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
11/5/2025 - Globe Newswire
HUTCHMED Completes Enrollment for Key Lung Cancer Trial
11/5/2025 - TipRanks Financial Blog
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS and TAGRISSO Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO
11/5/2025 - Globe Newswire
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript
11/4/2025 - SeekingAlpha
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 - Slideshow
11/4/2025 - SeekingAlpha
HUTCHMED (China) (HCM, $15.31) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 3, 2025
11/4/2025 - Tickeron - Stocks
HUTCHMED (China) (HCM, $15.31) Stochastic Oscillator left the oversold zone on November 03, 2025
11/4/2025 - Tickeron - Stocks
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Rating of "Hold" from Brokerages
11/4/2025 - Ticker Report
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
11/3/2025 - Globe Newswire
HUTCHMED (China) (HCM, $14.68) RSI Indicator left the oversold zone on October 31, 2025
11/1/2025 - Tickeron - Stocks
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
10/31/2025 - SeekingAlpha
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
10/31/2025 - Seeking Alpha: Transcripts
Income Statement
Total Revenue (TTM)
$602.20M
EBITDA (TTM)
-$7.49M
EBIT (TTM)
-$19.70M
Net Income (TTM)
$466.88M
Balance Sheet
Total Assets (Q)
$1.78B
Total Debt (Q)
$100.73M
Total Liabilities (Q)
$534.02M
Book Value Per Share (Q)
$1.43
Cash Flow
Cash from Operations (TTM)
-$32.57M
Cash from Investing (TTM)
-$73.03M
Cash from Financing (TTM)
$11.22M
Net Change in Cash (TTM)
-$93.23M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Loading...
Beta
0.67
7-Day Total Return
1.86%
30-Day Total Return
-6.18%
60-Day Total Return
-11.15%
90-Day Total Return
-20.69%
Year to Date Total Return
-5.44%
1-Year Total Return
-17.90%
2-Year Total Return
-20.42%
3-Year Total Return
4.01%
5-Year Total Return
-52.08%
52-week Low
Apr 09, 2025 - $11.51
52-week High
Jul 29, 2025 - $19.50
Valuation
Market Cap
$2.51B - Mid Cap
Enterprise Value
$1.30B
Price/Sales (TTM)
20.66
Price/Book (Q)
9.97
Dividends and Shares
Shares Outstanding
872.56
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.hutch-med.com
Phone Number
852 2121 8200
Address
Cheung Kong Center
48th floor - 2 Queen's Road Central
Hong Kong,
Country
Hong Kong
Year Founded
2000
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed